Advanced in Primary Biliary Cholangitis

Dr. Nikolaos Pyrsopoulos

Hepatology
New York University
550 1st Ave, 
New York, NY 
29 Years of Experience
Advanced in Primary Biliary Cholangitis
New York University
550 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nikolaos Pyrsopoulos is a Hepatologist in New York, New York. Dr. Pyrsopoulos has been practicing medicine for over 29 years and is rated as an Advanced provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Liver Failure, Hepatitis, Hepatorenal Syndrome, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Primary Biliary Cholangitis.

Specialties
Hepatology
Licenses
Internal Medicine in NY
Hospital Affiliations
Nyu Langone Hospitals
Morristown Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

NEW YORK UNIVERSITY
550 1st Ave, New York, NY 10016
Other Locations
PRACTICE ASSOCIATES MEDICAL GROUP
33 Overlook Rd, Summit, NJ 07901
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Additional Areas of Focus

Dr. Pyrsopoulos has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)
Enrollment Status: Terminated
Publish Date: January 25, 2019
Intervention Type: Biological, Other
Study Phase: Phase 3
68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma
68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma
Enrollment Status: Unknown
Publish Date: January 03, 2019
Intervention Type: Drug
Study Drug: 68Gallium Citrate
Study Phase: Phase 2
View 5 Less Clinical Trials

97 Total Publications

Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.
Bacterial Infections in Patients With Severe Alcohol-Associated Hepatitis: Drivers of Organ Failure and Mortality.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: February 04, 2025
Similar Doctors
Elite in Primary Biliary Cholangitis
Dr. Joseph Odin
Hepatology
Elite in Primary Biliary Cholangitis
Dr. Joseph Odin
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (3.3 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Odin is a Hepatologist in New York, New York. Dr. Odin is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Distinguished in Primary Biliary Cholangitis
Dr. Nancy Bach
Hepatology
Distinguished in Primary Biliary Cholangitis
Dr. Nancy Bach
Hepatology

Icahn School Of Medicine At Mount Sinai

1450 Madison Ave, 
New York, NY 
 (3.4 miles away)
212-241-8545
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nancy Bach is a Hepatologist in New York, New York. Dr. Bach is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. Her top areas of expertise are Primary Biliary Cholangitis, Reynolds Syndrome, Hepatitis, Cirrhosis, and Liver Transplant.

Distinguished in Primary Biliary Cholangitis
Dr. Ira Jacobson
Hepatology
Distinguished in Primary Biliary Cholangitis
Dr. Ira Jacobson
Hepatology

New York University

530 1st Ave, 
New York, NY 
 (0.1 miles away)
212-263-7300
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Hepatologist in New York, New York. Dr. Jacobson has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Liver Transplant, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pyrsopoulos's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile